Kazia Therapeutics
KZIA
6 hedge funds and large institutions have $531K invested in Kazia Therapeutics in 2018 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
97% more capital invested
Capital invested by funds: $269K → $531K (+$262K)
20% more funds holding
Funds holding: 5 → 6 (+1)
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$37.5K |
| 2 |
Morgan Stanley
New York
|
+$18.5K |
| 3 |
RE
RBC Europe
London,
United Kingdom
|
+$231 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$9.72K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $281K | +$18.5K | +80 | +9% |
|
2
Renaissance Technologies
New York
| $193K | – | – | – |
|
|
3
Acadian Asset Management
Boston,
Massachusetts
| $45K | +$37.5K | +162 | New |
|
4
Royal Bank of Canada
Toronto,
Ontario, Canada
| $7K | – | – | – |
|
|
5
UBS Group
Zurich,
Switzerland
| $5K | -$9.72K | -42 | -69% |
|
|
RE
6
RBC Europe
London,
United Kingdom
| $180 | +$231 | +1 | New |
|
KZIA Hedge Fund Activity: Q1 2018 in Review
6 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Kazia Therapeutics (KZIA) for Q1 2018, worth a combined $531K — up 97% from $269K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new KZIA positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Acadian Asset Management, opening a new position worth an estimated $37.5K. The largest seller was UBS Group, cutting an estimated $9.72K.
- 6 institutional investors held Kazia Therapeutics (KZIA) as of Q1 2018, up from 5 in Q4 2017.
- Funds reported $531K of Kazia Therapeutics stock for Q1 2018, up 97% quarter-over-quarter.
- 2 funds opened new Kazia Therapeutics positions in Q1 2018 and 1 closed out, a net change of +1 holder.
- The largest Kazia Therapeutics buyer in Q1 2018 was Acadian Asset Management, an estimated $37.5K added.
- The largest Kazia Therapeutics seller in Q1 2018 was UBS Group, an estimated $9.72K sold.
Based on aggregated 13F filings for Q1 2018.